Back to search

Article

GD2-specific Chimeric Antigen Receptor-modified T Cells for the treatment of Refractory and/or Recurrent Neuroblastoma in Pediatric Patients

2021-08-18

Abstract excerpt

<title>Abstract</title> <p>PurposeThis study aimed to evaluate the safety and efficacy of the fourth-generation chimeric antigen receptor (CAR) disialoganglioside 2 (GD2)-specific (4SCAR-GD2) T cells for treatment of refractory and/or recurrent neuroblastoma (NB) in pediatric patients. Experimental DesignA phase I clinical study using 4SCAR-GD2 T cells for the treatment of NB in pediatric patients was conducted....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
67874813-2a16-596b-994e-df3688ee10f0
DOI
10.21203/rs.3.rs-803629/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
GD2-specific Chimeric Antigen Receptor-modified T Cells for the treatment of Refractory and/or Recurrent Neuroblastoma in Pediatric PatientsDOI 10.21203/rs.3.rs-803629/v1
GD2 targeting CAR T cells for neuroblastomaSemantic proximity
Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors: A Systematic Review and Meta-AnalysisSemantic proximity
An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other CancersSemantic proximity
Immunotherapy of Neuroblastoma: Facts and HopesSemantic proximity
Current Knowledge and Perspectives of Immunotherapies for NeuroblastomaSemantic proximity
Eighteen-year survival after GD2-directed Chimeric Antigen Receptor-Modified Immune Effector Cell Treatment for NeuroblastomaSemantic proximity
State of the Art in Immunotherapy of NeuroblastomaSemantic proximity
Biological Insight and Recent Advancement in the Treatment of NeuroblastomaSemantic proximity
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with NeuroblastomaSemantic proximity
Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression.Semantic proximity
Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe NeuroblastomaSemantic proximity
Next-Generation Chimeric Antigen Receptor T-cellsSemantic proximity
Select a neighboring publication to make it the new centre.